06.03.2012 07:35 Uhr, Quelle: Wallstreet online

MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial

MorphoSys AG / MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Study Data Expected in Q3 …

Weiterlesen bei Wallstreet online

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz